These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Companies jostle for access to public markets. Bouchie A Nat Biotechnol; 2003 Dec; 21(12):1413-4. PubMed ID: 14647309 [No Abstract] [Full Text] [Related]
7. IPOs: the narrow window closes? Lawrence S Nat Biotechnol; 2004 Dec; 22(12):1489. PubMed ID: 15583641 [No Abstract] [Full Text] [Related]
8. Looking at US versus European exit opportunities. Lawrence S Nat Biotechnol; 2005 Oct; 23(10):1203. PubMed ID: 16302294 [No Abstract] [Full Text] [Related]
9. Mind the (biomedical funding) gap. Klausner A Nat Biotechnol; 2005 Oct; 23(10):1217-8. PubMed ID: 16211055 [No Abstract] [Full Text] [Related]
10. The rise of European venture capital for biotechnology. Howell M; Trull M; Dibner MD Nat Biotechnol; 2003 Nov; 21(11):1287-91. PubMed ID: 14595356 [No Abstract] [Full Text] [Related]
13. Korean biotechs seize opportunity to list on public markets. Louët S Nat Biotechnol; 2005 Oct; 23(10):1189-90. PubMed ID: 16211042 [No Abstract] [Full Text] [Related]
14. Public markets show signs of life. Mitchell P Nat Biotechnol; 2003 Aug; 21(8):833-4. PubMed ID: 12894181 [No Abstract] [Full Text] [Related]
15. The responsibilities of growing up. Nat Biotechnol; 2006 Mar; 24(3):225. PubMed ID: 16525362 [No Abstract] [Full Text] [Related]
16. VC funding hits high in Q1. Lawrence S Nat Biotechnol; 2007 May; 25(5):496. PubMed ID: 17483825 [No Abstract] [Full Text] [Related]
18. Mixed results in Q1. Lawrence S Nat Biotechnol; 2005 May; 23(5):518. PubMed ID: 15877059 [No Abstract] [Full Text] [Related]
19. IPO plans sour on both sides of the pond. Mitchell P Nat Biotechnol; 2004 Aug; 22(8):929-30. PubMed ID: 15286629 [No Abstract] [Full Text] [Related]